Gilead Sees 2026 Loss on $11.5 Billion in Deal-Related Charges

Gilead Sciences Inc. said it now expects to book a loss in 2026 on $11.5 billion in charges after deals to acquire a string of companies making experimental cancer and...

By Robert Langreth · Bloomberg

Gilead Sciences Inc. said it now expects to book a loss in 2026 on $11.5 billion in charges after deals to acquire a string of companies making experimental cancer and autoimmune disease drugs.